OXFORD University’s coronavirus vaccine triggers an immune response at all ages – including the elderly, new results released Thursday reveal. In a milestone, the jab – in development with AstraZeneca – has been shown to “trigger a robust immune response” without serious side effects in those aged 56-69 and over 70. Phase two data from the ChAdOx1 nCov-2019 vaccine raises hopes of phase three efficacy readings “in the coming weeks.” Responding to the news, Health Secretary Matt Hancock tweeted: “There is still a lot of work to do, but this is a set of really encouraging conclusions from the @UniofOxford and @AstraZeneca vaccines.” The UK government has pre-ordered 100 million doses of the jab, of which four million are expected to be available next month – if given the green light. Professor Andrew Pollard, head of the Oxford vaccine testing team, said today it was too early to know the vaccine’s effectiveness – but the results of late-stage trials “certainly should be known before Christmas “. Once the results of phase three are released, AstraZeneca will have to wait for final safety data before they can apply to the MHRA here, and the FDA in the United States for approval. Only then could the jabs be rolled out, with the NHS on hold from December 1. Read more University of Oxford’s Covid vaccine ‘triggers antibodies in older people’ and UK has already ordered 100 million doses How the University of Oxford’s Covid vaccine works – and it could it be better than that of Pfizer? From the latest Brexit news to HD movie trailers, The Sun newspaper brings you the latest videos and explanations from the UK and around the world. Become a Sun subscriber and hit the bell to be the first to know Read the Sun: Love the Sun on Facebook: Follow the Sun on Twitter: Subscribe to the Sun on Snapchat :.
#Oxford #Covid19 #hit #detected #trigger #antibodies #elderly